REFERENCES

1. Ault P, Jones K. Understanding iron overload: screening, monitoring, andcaring for patients with transfusion-dependent anemias. Clin J Oncol Nurs.2009;13(5):511-517.
2. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986-1995.
3. Cappellini MD, Taher A. Deferasirox (Exjade®) for the treatment of ironoverload. Acta Haematol. 2009;122(2-3):165-173.
4. VanOrden HE, Hagemann TM. Deferasirox—an oral agent for chronic ironoverload. Ann Pharmacother. 2006;40(6):1110-1117.
5. Cappellini MD, Cohen A, Eleftheriou A, et al, eds. Guidelines for the ClinicalManagement of Thalassaemia. 2nd revised ed. Nicosia, Cyprus: ThalassaemiaInternational Federation; 2008.
6. Fung EB, Harmatz P, Milet M, et al. Morbidity and mortality in chronicallytransfused subjects with thalassemia and sickle cell disease: A report fromthe multi-center study of iron overload. Am J Hematol. 2007;72(4):255-265.
7. National Library of Medicine. Genetics Home Reference. Beta thalassemia.Available at: http://ghr.nlm.nih.gov/condition=betathalassemia. AccessedJanuary 4, 2010.
8. Kwiatkowski JL. Oral iron chelators. Pediatr Clin N Am. 2008;55(2):461-482.
9. Centers for Disease Control and Prevention. Thalassemia. Available at:http://www.cdc.gov/ncbddd/hbd/thalassemia.htm. Accessed January 19,2010.
10. Haywood C, Beach MC, Lanzkrons S, et al. A systemic review of barriersand interventions to improve appropriate use of therapies for SCD.J Natl Med Assoc. 2009;101(10):1022-1033.
11. National Heart, Lung and Blood Institute. The Management of Sickle CellDisease. 4th Ed. Bethesda, Md: National Institutes of Health; 2002. NIHpublication 02-2217.
12. Galanello R, Piga A, Cappellini MD, et al. Effect of food, type of food, andtime of food intake on deferasirox bioavailability: recommendations foran optimal deferasirox administration regimen. J Clin Pharmacol.2008;48(4):428-435.
13. National Comprehensive Cancer Network (NCCN). NCCN Clinical PracticeGuidelines in Oncology. Myelodysplastic Syndromes. V2.2010. http://www.nccn.org.
14. Tefferi A, Vardiman JW. Myelodysplastic Syndromes. N Engl J Med.2009;361(19):1872-1885.
15. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplasticsyndromes and chronic myeloproliferative disorders in the United States,2001-2004, using data from the NAA CCR and SEER programs. Blood.2008;112(1):45-52.
16. Cappellini MD, Taher A. Long-term experience with deferasirox (ICL670),a once-daily oral iron chelator, in the treatment of transfusional ironoverload. Expert Opin Pharmacother. 2008;9(13):2391-2402.
17. Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM. Managing iron overloadin patients with myelodysplastic syndromes with oral deferasirox therapy.The Oncologist. 2009;14(5):489-496.
18. International Association of Sickle Cell Nurses & Physician Assistants(IASCNAPA). Nursing practice guidelines: care of the patient with sicklecell disease and iron overload. 2008. http://www.iascnapa.org/guidelines/Guidelines_IronOverload.pdf. Accessed December 17, 2009.
19. Screening and monitoring for iron overload. www.irontoxicity.com.Accessed January 4, 2010.
20. National Library of Medicine. Ferritin. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/003490.htm. Accessed January 4, 2010.
21. Exjade [package insert]. East Hanover, NJ: Novartis PharmaceuticalsCorporation; 2010.
22. Mir MA, Logue GL. Transfusion-induced iron overload. eMedicine.com.2008. http://emedicine.medscape.com/article/1389732-overview. AccessedDecember 17, 2008.
23. Desferal [package insert]. East Hanover, NJ: Novartis PharmaceuticalsCorporation; 2007.
24. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670),a once-daily oral iron chelator, in patients with beta-thalassemia. Blood.2006;107(9):3455-3462.
25. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox,a once-daily oral chelating agent, in pediatric patients with beta-thalassemiamajor. Haematologica. 2006;91(10):1343-1351.
26. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox(Exjade®, ICL670), a once-daily, orally-administered iron chelator, incomparison to deferoxamine in thalassemia patients with transfusionaliron overload. Haematologica. 2006;91(7):873-880.
27. Porter J, Galanello R, Saglio G, et al. Relative response of patients withmyelodysplastic syndromes and other transfusion-dependent anaemiasto deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol.2008;80(2):168-176.
28. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison ofdeferasirox versus deferoxamine for the treatment of transfusional ironoverload in sickle cell disease. Br J Haematol. 2007;136(3):501-508.
29. Taher A, Cappellini MD. Update on the use of deferasirox in the managementof iron overload. Ther Clin Risk Manag. 2009;5:857-868.
30. Data on file. Novartis Pharmaceuticals Corporation. 2009.
31. Cappellini M, El-Beshlawy A, Kattamis A, et al. Efficacy and safety ofdeferasirox (Exjade®) in patients with transfusion-dependent anemias:1-year results from the large, prospective, multicenter EPIC study. Blood.2008;112(11): abstract 3875.
32. Gattermann N. Efficacy and safety of deferasirox (Exjade®) during 1 yearof treatment in transfusion-dependent patients with myelodysplasticsyndromes: results from the EPIC trial. Blood. 2008;112(11): abstract 633.
33. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox,an oral iron chelator, in heavily iron-overloaded patients with betathalassaemia:the ESCALATOR study. Eur J Haematol. 2009;82(6):458-465.
34. Taher A, El-Beshlawy A, Elalfy M, et al. Deferasirox significantly reducesiron burden in heavily iron-overloaded patients with beta-thalassaemia:2.7 year results from the ESCALATOR study. Haematologica. 2009;94(Suppl 2): abstract 209.
35. Pennell D, Porter JB, Cappellini MD, et al. Efficacy and safety of deferasirox(Exjade®) in reducing cardiac iron in patients with β-thalassemia major,results from the cardiac substudy of the EPIC trial. Blood. 2008;112(11):abstract 3873.
36. Wood JC, Thompson AA , Paley C, et al. Deferasirox (Exjade®) monotherapysignificantly reduces cardiac iron burden in chronically transfusedβ-thalassemia patients: an MRI T2* study. Blood. 2008;112(11): abstract3882.
37. Reyal Y, Chowdhury O, Kirk P, et al. Improvement in cardiac T2* withdeferasirox in transfused patients with cardiac iron overload. Haematologica.2008;93(Suppl 1): abstract 846.
38. Garbowski M, Eleftheriou P, Pennell D, et al. Impact of compliance, ferritinand LIC on long-term trends in myocardial T2* with deferasirox. Blood.2008;112(11): abstract 116.
39. Pennell D, Sutcharitchan P, El-Beshlawy A, et al. Efficacy and safety ofdeferasirox (Exjade®) in preventing cardiac iron overload in β-thalassemiapatients with normal baseline cardiac iron: results from the cardiac substudyof the EPIC trial. Blood. 2008;112(11): abstract 3874.
40. Pathare A, Taher A, Daar S. Deferasirox (Exjade®) significantly improvescardiac T2* in heavily iron-overloaded patients with β-thalassemia major.Ann Hematol. Published online 02 Oct 2009.
41. Schmid M, Cappellini MD, Porter JB, et al. Safety of deferasirox (Exjade®)in myelodysplastic syndromes (MDS) and non-MDS patients withtransfusional iron overload: a pooled analysis focusing on renal function.Blood. 2009;114(22): abstract 1768.
42. Gattermann N, Leismann O, Schlag R, et al. Deferasirox (Exjade) treatmentof chelation-naive and pre-chelated MDS patients with transfusionaliron-overload in the medical practice: Results from the observationalstudies Extend and Exjange. Blood. 2009;114(22): abstract 3805.
43. List AF, Baer MR, Steensma D, et al. Two year analysis of deferasiroxtreatment efficacy and safety in myelodysplastic syndrome patients inthe US03 study. Blood. 2009;114(22): abstract 3829.
44. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluationof patient-reported outcomes during treatment with deferasirox ordeferoxamine for iron overload in patients with β-thalassemia. Clin Ther.2007;29(5):909-917.
45. Cioffi G, Bates B, Butler C, et al. Exploring barriers and facilitators totreatment adherence among people with thalassemia and theircaregivers. 2009. http://www.thalassemia.org/updates/pdf/BarriersFacil.pdf. Accessed February 18, 2010.
46. Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes ofdeferasirox (Exjade, ICL670) versus deferoxamine in sickle cell diseasepatients with transfusional hemosiderosis. Substudy of a randomizedopen-label phase II trial. Acta Haematol. 2008;119(3):133-141.
47. Pilo F, Di Tucci AA , Dessi L, Angelucci E. Management of transfusional ironoverload: focus on deferasirox. Clin Med Ther. 2009;1:735-745.
48. Vichinsky E. Clinical application of deferasirox: practical patient management.Am J Hematol. 2008;83(5):398-402.
49. Iron Overload Nurse Ambassador Program (IONA). Management of irontoxicity. http://www.ironoverloadnurses.com. Accessed January 4, 2010.
50. Cianciulli P. Treatment of iron overload in thalassemia. Pediatr EndocrinolRev. 2008;6(Suppl 1):208-213.
51. Raphael JL, Bernhardt MB, Mahoney DH, et al. Oral iron chelation and thetreatment of iron overload in a pediatric hematology center. Blood Cancer.2009;52(5):616-620.
52. Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplasticsyndromes. An analysis of 205 patients in 17 studies. Br J Haematol. 1995;89(1):67-71.
53. Hellström–Lindberg E, Gulbrandsen N, Lindberg G, et al. A validateddecision model for treating the anaemia of myelodysplastic syndromeswith erythropoietin + granulocyte colony-stimulating factor: significanteffects on quality of life. Br J Haematol. 2003;120(6):1037-1046.